Mineshima, Michio
,
Kawanishi, Hideki
Ase, Tomonobu
Kawasaki, Tadayuki
Tomo, Tadashi
Nakamoto, Hidetomo
Article History
Received: 13 December 2017
Accepted: 13 February 2018
First Online: 21 March 2018
Ethics approval and consent to participate
: Not applicable
: This manuscript does not contain any data relating to individuals.
: The authors declare the following conflicts of interest:Michio Mineshima has been receiving technical advisory fees, honoraria, and grants-in-aid for research from JMS Co., Ltd. (a company that manufactures, markets, imports and exports medical devices and pharmaceuticals), and Nipro Co., Ltd. (a company that conducts R&D of medical devices and pharmaceuticals).Hideki Kawanishi has been receiving honoraria from Chugai Pharmaceutical Co., Ltd. (a company that manufactures, markets, imports, and exports ethical drugs), Kyowa Hakko Kirin Co., Ltd. (a company that manufactures and markets ethical drugs), and Bayer Yakuhin, Ltd. (a company that develops, imports, manufactures, and markets pharmaceuticals, medical devices, and drugs for animals).Tomonobu Ase has been receiving salary as a company employee of Daicen-Membrane Systems Ltd., has participated in formulating the management standard for water treatment equipment as a representative of the Committee on Dialysis water of the Association of Membrane Separation Technology of Japan and as an external member of this subcommittee.Hidetomo Nakamoto has been receiving honoraria and grants-in-aid for scientific research from Toray Industries, Inc. (a company that manufactures and markets pharmaceutical and medical care products), Astellas Pharma Inc. (a company that manufactures, markets, exports, and imports pharmaceutical products), Baxter Limited (a company that imports, manufactures, and markets dialysis products, plasma protein preparations, and drug delivery systems), Chugai Pharmaceutical Co., Ltd. (a company that manufactures, markets, imports, and exports ethical drugs), Kyowa Hakko Kirin Co., Ltd. (a company manufacturing and marketing ethical drugs), Terumo Corporation (a company that manufactures and markets medical devices and pharmaceuticals), Kissei Pharmaceutical Co., Ltd. (a company that conducts R&D and manufactures and markets ethical drugs), Chugai Pharmaceutical Co., Ltd. (a company that manufactures, markets, imports, and exports ethical drugs), Sumitomo Dainippon Pharma Co., Ltd. (a company that manufactures and markets ethical drugs, diagnostic drugs, etc.), and Takeda Pharmaceutical Company Limited (a company that manufactures, markets, imports, and exports pharmaceutical products, quasi drugs, etc.).The other authors declare that they have no competing interests.